GlaxoSmithKline: Depressive Disorder, Major trials
The registry lists 29 Depressive Disorder, Major studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 3Phase 2 14Phase 3 8Phase 4 2No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive DisorderCompletedNCT02191397Phase 3Results posted
- A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)CompletedNCT01138007Phase 3Results posted
- Clinical Study to Test a New Drug to Treat Major DepressionCompletedNCT00976560Phase 2Results posted
- Safety and Efficacy Study in Patients With Major Depressive DisorderCompletedNCT00896363Phase 2Results posted
- A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive DisorderTerminatedNCT00880399Phase 2Results posted
- A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive DisorderCompletedNCT00733980Phase 2Results posted
- MDD POC Study GSK372475 Subjects Depressive DiseaseCompletedNCT00420641Phase 2Results posted
- Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In JapanCompletedNCT00330616Phase 2Results posted
- A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated RisksCompletedNCT03001440
- A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy VolunteersCompletedNCT02698553Phase 1
- PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011CompletedNCT02039960
- First Time in Human StudyCompletedNCT01031186Phase 1
- A Study of GW856553X For the Treatment of DepressionTerminatedNCT00569062Phase 2
- Patient Tolerability Study of GSK163090CompletedNCT00559299Phase 1
- A Study Of New Medicine (GSK 372475) For The Treatment Of DepressionCompletedNCT00448058Phase 2
- Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)CompletedNCT00413023Phase 2
- A Local Register Study For Major Depression Of Paroxetine Controlled ReleaseCompletedNCT00368303Phase 3
- Sexual Functioning Study With AntidepressantsCompletedNCT00316160Phase 4
- Study Of GW679769 In Major Depressive DisorderCompletedNCT00102492Phase 2
- Major Depressive Disorder In The ElderlyCompletedNCT00093288Phase 3
- Depression Study In Elderly PatientsCompletedNCT00067444Phase 3
- Lethargic Depression StudyCompletedNCT00064467Phase 3
- An 8 Week Depression Study In Adults Diagnosed With Major Depressive DisorderCompletedNCT00057239Phase 2
- An 8 Week Study Of Adults Diagnosed With Major Depressive DisorderCompletedNCT00057226Phase 2
- An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive DisorderCompletedNCT00057213Phase 2
- Effects Of Antidepressants On Sexual Functioning In AdultsCompletedNCT00051272Phase 3
- Effects of Antidepressants on Sexual FunctioningCompletedNCT00051259Phase 3
- Major Depressive Disorder Study In AdultsCompletedNCT00049972Phase 4
- A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive DisorderCompletedNCT00048204Phase 2